What you need to know about the candidates’ views on healthcare.
Hobson
Wolfson
In the first 2020 Democratic presidential debates in Miami, 20 Democratic presidential candidates took the stage.
“Polling shows healthcare to be the number one issue among voters,” says Julius Hobson, Jr., senior policy advisor, at Polsinelli, a firm with offices in Washington, D.C. “The Democratic debates illustrate most of the candidates understand the need to address the issue.”
All candidates are clearly left of center on health policy, says Jay Wolfson, DrPH, JD, associate vice president for health law, policy, and safety at the Morsani College of Medicine at the University of South Florida. “There was not a single reference to personal responsibility, only the obligation of the government to provide.”
Here are the top healthcare policy takeaways from the debate:
Related: What Will Trump’s Price Transparency Executive Order Do?
2023 Drug Trend Report - Xevant
May 16th 2024To effectively navigate the changing pharmacy landscape and maintain a robust, cost-effective pharmacy benefit, you must understand the forces behind rising drug trend. What’s driving your costs and what can you do about it? As a leader in the PBM analytics space, we offer a unique perspective on pivotal trend drivers. Here’s what our comprehensive analysis revealed: -A surge in utilization rates across specialty and non-specialty drugs, magnified by anti-obesity therapies -Financial strain imposed by anti-inflammatory biologics and the yet-to-be-fulfilled -promise of biosimilar savings -Persistent price inflation driving higher costs year over year
Read More
Two Opdivo Updates from Bristol Myers Squibb
May 14th 2024First approved by the U.S. Food and Drug Administration (FDA) in 2014, Opdivo has multiple indications across various types of cancer, including NSCLC, melanoma, renal cell carcinoma, Hodgkin lymphoma, squamous cell carcinoma of the head and neck, and urothelial carcinoma.
Read More